James L. Abbruzzese – författare

In 74 chapters, Gastrointestinal Oncology brings together a diverse group of specialists to provide the most authoritative, up-to-date and encyclopedic volume currently available on the subject. The first part of this text introduces a series of concepts and topics that are important to gastrointestinal malignancies in general. These topics include epidemiologic principles, prevention, screening, familial GI cancers, developmental and molecular biology, pathobiology, general therapeutic principles, emerging therapies, and palliative care. The second part of the book covers each of the specific cancers affecting the human gastrointestinal tract. These chapters are introduced by state of the art discussions outlining our current understanding of the pathobiology and molecular biology relevant to each cancer. Subsequent sections describe the multidisciplinary management of specific clinical situations. By organizing the treatment-related chapters around clinical scenarios, the reader will readily find the information necessary to effectively manage the complex clinical situations encountered by patients with gastrointestinal malignancies.

In 74 chapters, Gastrointestinal Oncology brings together a diverse group of specialists to provide the most authoritative, up-to-date and encyclopedic volume currently available on the subject. The first part of this text introduces a series of concepts and topics taht are important to gastrointestinal malignancies in general. These topics include epidemiologic principles, prevention, screening, familial GI cancers, developmental and molecular biology, pathobiology, general therapeutic principles, emerging therapies, and palliative care. The second part of the book covers each of the specific cancers affecting the human gastrointestinal tract. These chapters are introduced by state of the art discussions outlining our current understanding of the pathobiology and molecular biology relevant to each cancer. Subsequent sections describe the multidisciplinary management of specific clinical situations. By organizing the treatment-related chapters around clinical scenarios, the reader will readily find the information necessary to effectively manage the complex clinical situations encountered by patients with gastrointestinal malignancies.

Top Investigators Explore the Complexities of Angiogenesis Cancer ResearchThe targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment.Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers.This volume celebrates progress made in four decades, and more importantly, it provi

Top Investigators Explore the Complexities of Angiogenesis Cancer ResearchThe targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment.Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers.This volume celebrates progress made in four decades, and more importantly, it provi

In organizing the second edition of  this renowned Handbook, Dr. Neoptolemos and his co-editors have produced and updated a revised edition to the distinguished Major Reference Work devoted to pancreatic cancer. Like its preceding edition, the second edition continues to have a widespread appeal among clinicians, pathologists and basic scientists, who are now struggling to understand this complex and rapidly expanding field. Because of the recent and vast growth in both the clinical and scientific research being done in pancreatic cancer, (there is currently an unprecedented investment by academia and industry in this field), each research’s knowledge of other specialty areas outside his or her own is often quite limited. The aim of the new edition is to place the tangible advances, including new developments in surgical approaches with regards to resection techniques, the state of laparoscopic approaches, the growing impact of surgical approaches in the management of recurrent pancreatic cancer, controversies in the management of IMPN as the precursor lesion for PDAC and others – readily at hand. The second edition focuses on advances that will not become dated, and the editors have chosen authors, who are the very best in each area.